Chroma and Sangamo sign agreement on epigenetic medicines leveraging zinc finger proteins
July 21, 2023
Sangamo Therapeutics Inc. and Chroma Medicine Inc. have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition.